DEF: Local Bounti Seeks Shareholder Vote on Stock Issuance

Local Bounti Corporation is holding a special meeting of stockholders on November 4, 2026, to vote on the approval of issuing up to 12,563,309 shares of common stock upon conversion of a convertible note and up to 1,000,000 shares underlying a warrant, both issued to U.S. Bounti, LLC.

Summary

• Local Bounti Corporation is convening a special meeting of stockholders on November 4, 2026, to vote on two proposals.
• Proposal 1, the NYSE Approval Proposal, seeks stockholder approval for the issuance of up to 12,563,309 shares of common stock upon conversion of a convertible note and up to 1,000,000 shares underlying a common stock purchase warrant. These instruments were issued to U.S. Bounti, LLC, the company's majority stockholder, on August 7, 2026.
• The approval is required to comply with New York Stock Exchange (NYSE) rules, as the issuance exceeds the 1% threshold for related party transactions and the conversion/exercise prices were below the NYSE Minimum Price.
• Proposal 2, the Adjournment Proposal, allows the company to adjourn the meeting if necessary to solicit additional proxies for Proposal 1.
• The record date for the meeting is September 18, 2026, and the meeting will be conducted virtually.
• The Board of Directors unanimously recommends a vote FOR both proposals.
• Failure to approve Proposal 1 may result in the company incurring additional costs by needing to call subsequent special meetings every four months until approval is obtained.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the necessity of seeking stockholder approval for a significant share issuance, which indicates potential dilution and reliance on external financing. The need for an adjournment proposal also suggests uncertainty in achieving the required votes.

Positives

• The company is proactively seeking stockholder approval to comply with NYSE regulations, demonstrating a commitment to governance.
• The Board of Directors unanimously supports the proposals, indicating management's belief in their necessity and benefit.
• The convertible note and warrant provide a mechanism for U.S. Bounti, LLC to convert its investment into equity, potentially strengthening the company's capital structure.
• The company has a clear process for virtual attendance and voting, ensuring accessibility for stockholders.

Negatives

• The issuance of up to 13,563,309 shares (12,563,309 + 1,000,000) represents a significant potential dilution to existing stockholders, as it could amount to over 50% of the currently outstanding shares (23,381,516 shares as of the record date).
• The conversion price of $1.37 per share and the warrant exercise price of $0.125 per share are below the NYSE Minimum Price, necessitating stockholder approval.
• The need for an Adjournment Proposal suggests potential difficulty in securing sufficient votes for the primary proposal, indicating investor uncertainty or opposition.
• If Proposal 1 is not approved, the company will be obligated to hold additional special meetings every four months, incurring further costs and delaying the potential equity conversion.

Risks

• Potential for significant dilution of existing shareholders' equity and earnings per share if the convertible note and warrant are fully converted/exercised.
• Adverse impact on the trading price of common stock if significant quantities of shares are sold by U.S. Bounti, LLC following approval and registration.
• The concentration of ownership by Charles R. Schwab (74.3%) and U.S. Bounti, LLC (majority stockholder) could influence corporate decisions and potentially deter unsolicited takeover offers.
• The company may incur additional costs and delays if stockholder approval for the share issuance is not obtained at the special meeting.

Future Outlook

The filing does not contain specific forward-looking financial guidance. The primary forward-looking aspect relates to the potential conversion of the convertible note and exercise of the warrant, which is contingent on stockholder approval and market conditions.

Management Comments

• The Board of Directors unanimously recommends that you vote FOR the items described in the accompanying proxy statement.
• The Board and our management support the NYSE Approval Proposal and believe it to be in the best interests of Local Bounti and our stockholders.
• We expect that the NYSE Approval Proposal will receive a sufficient number of votes at the Special Meeting to ensure that it is approved.

Industry Context

StockSavvy.ai notes that seeking stockholder approval for significant share issuances, especially to related parties or at prices below market indicators, is a common but often scrutinized event in the biotechnology and technology sectors. Compliance with exchange rules like those of the NYSE is critical for maintaining listing status.

Comparison to Industry Standards

• The NYSE requires stockholder approval for issuances exceeding 1% of outstanding shares to related parties if the price is below the Minimum Price. This is a standard regulatory requirement to protect minority shareholders.
• The potential dilution from issuing up to 13.5 million shares on top of 23.3 million outstanding shares is substantial. Industry standards for acceptable dilution vary by sector and growth stage, but such a large percentage increase would typically be met with significant investor scrutiny.
• The structure of the convertible note, with automatic conversion on anniversaries and maturity, is a common financing tool, but the terms (conversion price, PIK interest) are specific to the company's situation and negotiation with U.S. Bounti, LLC.

Related Party Transactions

• The core of this filing concerns the proposed issuance of shares to U.S. Bounti, LLC, which is the company's majority stockholder and controlled by Charles R. Schwab.
• The Convertible Note and Warrant Purchase Agreement dated August 7, 2026, is a related party transaction requiring stockholder approval under NYSE rules due to the percentage of shares to be issued and the pricing terms.
• Charles R. Schwab beneficially owns 74.3% of the outstanding common stock, and U.S. Bounti, LLC has the right to appoint two directors, highlighting significant related party influence.

Stakeholder Impact

• Existing shareholders face potential dilution of their ownership percentage and per-share metrics (like EPS and book value) if the convertible note is converted and the warrant is exercised.
• The potential for increased share supply could negatively impact the stock's market price.
• Employees holding stock options or RSUs may see their equity diluted.
• Creditors may be impacted by changes in the company's capital structure and equity base.

Next Steps

• Stockholders will vote on the NYSE Approval Proposal and the Adjournment Proposal at the Special Meeting on November 4, 2026.
• If approved, U.S. Bounti, LLC may convert the note and exercise the warrant, leading to the issuance of new shares.
• If not approved, the company will be obligated to call additional special meetings every four months until approval is obtained.
• The company will file a registration statement to register the Conversion Shares and Warrant Shares for resale by U.S. Bounti, LLC, following approval.

Key Dates

Recommendation

The filing presents a mixed outlook. While the company is addressing NYSE compliance and securing financing, the significant potential dilution and the need for an adjournment proposal suggest underlying concerns about valuation and investor sentiment. A 'hold' recommendation reflects the uncertainty and the balance between potential capital infusion and dilutionary impact.

Keywords

stockholder approval, share issuance, convertible note, warrant, NYSE rules, dilution, special meeting, U.S. Bounti